Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.38 |
| ▸ | NOS2 | P35228 | 3/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7856561 | 1.00 | NOS1 (0.38) | NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL38199 | 0.97 | NOS1 (0.39) | NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL6860548 | 0.97 | NOS1 (0.39) | NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL6470302 | 0.94 | NOS1 (0.41) | NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL8391462 | 0.94 | NOS1 (0.41) | NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL7854014 | 0.94 | NOS1 (0.41) | NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL8397070 | 0.94 | NOS1 (0.41) | NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL8396522 | 0.94 | NOS1 (0.41) | NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL7853007 | 0.94 | NOS1 (0.41) | NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL7844870 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870656-B2 | Methods for treatment of heart failure | CARDURION PHARMACEUTICALS, LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190211028-A1 | METHODS FOR TREATMENT OF HEART FAILURE | CARDURION PHARMACEUTICALS LLC (US) | 2019-07-11 | — | — | US | disclosed |
| EP-3481399-A1 | METHODS FOR TREATMENT OF HEART FAILURE | Cardurion Pharmaceuticals, LLC (US) | 2019-05-15 | — | — | EP | disclosed |
| WO-2018009899-A1 | METHODS FOR TREATMENT OF HEART FAILURE | CARDURION PHARMACEUTICALS, LLC (US) | 2018-01-11 | — | — | WO | disclosed |
| EP-1908765-B1 | THIENOPYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2014-10-22 | — | — | EP | disclosed |
| US-8377944-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20130023546-A1 | THIENOPYRIMIDINE DERIVATIVES | GOTANDA KOTARO (JP) | 2013-01-24 | — | — | US | disclosed |
| US-8293754-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| WO-2012004900-A1 | THIENOPYRIMIDINE COMPOUNDS | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | WO | disclosed |
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1908765-A1 | THIENOPYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | BPHL, PDE12, UROD | NOS1 1399/4885NOS2 1314/4885NOS3 1538/4885 |
| US-10870656-B2 | Methods for treatment of heart failure | TNNT2, TNNI3, TNNC1 | NOS1 1985/4885NOS2 1170/4885NOS3 1054/4885 |
| US-20130023546-A1 | THIENOPYRIMIDINE DERIVATIVES | PDE9A, BPHL, THOP1 | NOS1 488/4885NOS2 637/4885NOS3 491/4885 |
| US-20090203703-A1 | Thienopyrimidine Derivatives | PDE9A, BPHL, THOP1 | NOS1 488/4885NOS2 637/4885NOS3 491/4885 |
| US-20190211028-A1 | METHODS FOR TREATMENT OF HEART FAILURE | TNNT2, TNNI3, TNNC1 | NOS1 1985/4885NOS2 1170/4885NOS3 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.